Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Wanner, Christoph ^a   Krane, Vera ^b   Ruf, Günther ^b   März, Winfried ^b   Ritz, Eberhard ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b NONE

Author keywords

Atorvastatin; Cholesterol; Diabetes; Triglycerides

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INHIBITION; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HYPERLIPIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0032973549     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. USRDS ANNUAL DATA REPORT. VI. CAUSES OF DEATH. Am J Kidney Dis 32(Suppl 1):S81-S88, 1998
2. USRDS ANNUAL DATA REPORT. IV. MEDICATION USE AMONG DIALYSIS PATIENTS IN THE DMMS. Am J Kidney Dis 32(Suppl 1):S38-S49, 1998
3. HERZOG CA, MA JZ, COLLINS AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-808, 1998
4. Deleted in proof.
5. UUSITUPA MIJ, NISKANEN LK, SIITONEN OM, VOUTILANAINEN E, PYÖRÄLÄ K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-diabetic and nondiabetic subjects. Circulation 82:27-86, 1990
6. TSCHÖPE W, KOCH M, THOMAS B, RITZ E: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Nephron 64:354-358, 1993
7. ATTMANN P-O, ALAUPOVIC P, GUSTAVSON A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32:368-375, 1987
8. SHOIJ T, NISHIZAWA Y, KAWAGISHI T, KAWASAKI K, TANIWAKI H, TABATA T, INOUE T, MORII H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9:1277-1284, 1998
9. QUASCHNING T, SCHÖMIG M, KELLER M, THIERY J, NAUCK M, SCHOLLMEYER P, WANNER C, KRÄMER-GUTH A: NIDDM and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 10:332-341, 1999
10. KOCH M, KUTKUHN B, GRABENSEE B, RITZ E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects. Nephrol Dial Transplant 12:2603-2611, 1997
11. BECKER BN, HIMMELFARB J, HENRICH WL, HAKIM RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
12. CRESSMANN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
13. KOCH M, KUTHUHN B, TRENKWALDER E, BACH D, GRABENSEE B, DIEPLINGER H, KRONENBERG F: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
14. KRONENBERG F: Homocysteine, lipoprotein(a) and fibrinogen: Metabolic risk factors for cardiovascular complications of chronic renal disease. Curr Opin Nephrol Hypertens 7:271-278, 1998
15. WU M-S, YU C-C, YANG C-W, WU C-H, HAUNG J-Y, HONG J-J, CHIANG C-YF, HUANG C-C, LEU M-L: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12:2105-2110, 1997
16. ZIMMERMANN J, HERRLINGER S, PRUY A, METZGER T, WANNER C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
17. BOLOGA RM, LEVINE DM, PARKER TS, CHEIGH JS, SERUR D, STENZEL KH, RUBIN AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114, 1998
18. NAUCK M, WINKLER K, MÄRZ W, WIELAND H: Quantitative determination of high-, low- and very low-density lipoprotein and lipo-protein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 41:1761-1767, 1995
19. NAWROCKI JW, WEISS SR, DAVISON MH, SPRECHER DL, SCHWARTZ SL, LUPIEN PJ, JONES PH, HABER HE, BLACK DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678-682, 1995
20. STERN RH, YANG BB, HORTON M, MOORE S, ABEL RB, OLSON SC: Renal dysfunction does not alter the pharmacokinetics or LDL cholesterol reduction of Atorvastatin. J Clin Pharmacol 37:816-819, 1997
21. AALEN OO, JOHANSEN S: An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Stat 5:141-150, 1997
22. PYÖRÄLÄ K, PEDERSEN TR, KJEKSIIUS J, FAERGEMAN O, OLSSON AG, THORGEIRSSON G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997